Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,432.82
(
-0.68%
)
US TECH 100
22,806.80
(
-0.63%
)
Dow Jones
45,550.21
(
-0.89%
)
Brent Oil
104.52
(
3.82%
)
Bitcoin
66,383.02
(
-3.49%
)
News Focus
News Focus
Post# of 257295
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122815
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: oc631 post# 163979

Friday, 07/12/2013 6:37:50 PM

Friday, July 12, 2013 6:37:50 PM

Post# of 257295
GILD—Russia doesn’t require the same level of evidence for drug approvals as the US, EU, Japan, and China (among others). Russia is rather more like India, where the supporting data can be scant.

Exhibit ‘A’ for Russia’s approval of a drug based on weak evidence: AGEN’s Oncophage (#msg-28291851).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Where Real Traders Talk Markets

Join thousands of traders sharing insights, catalysts, and charts.

Join Today